Pterostilbene: Human Evidence, LDL Signal, and Label Guide

Pterostilbene is a plant stilbene and a dimethylated analogue of resveratrol. The two compounds have related chemical structures, but they should not be treated as interchangeable ingredients or assumed to produce the same effects in people.

Researchers have detected pterostilbene in certain Vaccinium berries, including some blueberry species. The amounts measured in that food analysis were small and varied by species and cultivar. ¹ A capsule labeled blueberry extract is therefore not a known pterostilbene dose unless the label separately states or standardizes the pterostilbene amount.

A frequently cited pharmacokinetic study compared equimolar oral doses of pterostilbene and resveratrol in rats. Under those study conditions, pterostilbene had greater oral bioavailability and higher systemic exposure than resveratrol. ²

That was an animal study, not a human head-to-head trial. It does not establish greater absorption in people, a stronger clinical effect, better safety, or superior healthy-aging outcomes. The phrase more bioavailable should not be converted into better supplement without direct human evidence for the claimed result.

The most relevant standalone trial enrolled 80 adults with elevated total cholesterol or LDL cholesterol. Participants received 100 mg per day of pterostilbene, 250 mg per day, a pterostilbene and grape-extract combination, or placebo for 6 to 8 weeks. ^{4, 5}

When the pterostilbene-only groups were analyzed together, LDL cholesterol increased by 17.1 mg/dL compared with placebo. The 250 mg per day group also had lower office systolic and diastolic blood pressure than placebo. These were short-term surrogate outcomes from the same small, single-center study. They do not establish fewer cardiovascular events, treatment of hypertension, or overall heart benefit. ⁴

The cholesterol-medication subgroup is not a safety workaround

Baseline cholesterol medication appeared to attenuate the LDL result in a subgroup analysis. This does not show that a statin or another medicine prevents the effect, makes pterostilbene safe, or should be used to offset a supplement.

A heart-health claim should not rely on the blood-pressure result while ignoring the LDL result from the same trial. The LDL finding is a safety signal, not proof that every dose or formulation raises LDL in every person.

NAD+ formulas add another attribution problem

Pterostilbene is sometimes combined with nicotinamide riboside or NMN. An eight-week randomized study in 120 older adults found higher whole-blood NAD+ levels with nicotinamide riboside and pterostilbene combinations, but it had no pterostilbene-only arm. Total cholesterol and LDL cholesterol also increased from baseline in the combination groups, with larger increases in the double-dose group, although baseline differences between groups complicated interpretation. The study cannot show that pterostilbene caused the NAD+ change, establish synergy, or demonstrate slower aging. ⁸

When several active ingredients share one formula, connect each claim with the exact ingredient, amount, population, duration, and outcome studied. Do not transfer the result of the complete combination to pterostilbene alone.

Read surrounding ingredients separately

Resveratrol, quercetin, nicotinamide riboside, NMN, grape extract, and blueberry extract are separate ingredients. Their amounts should not be added to create a larger pterostilbene number. A long longevity stack can still leave the pterostilbene dose undisclosed.

For the wider method, read How to Read Supplement Labels and What Is a Proprietary Blend?

These examples compare disclosure quality. They do not rank real products, verify contents, or recommend a dose.

Transparency is not proof of effectiveness

Label B discloses more usable quantity information than Label C, but a calculable amount does not prove purity, stability, absorption, safety, or a health benefit. Clear disclosure answers what the formula claims to contain. It does not answer every question about the product.

Published human studies have used amounts from 10 to 250 mg per day for roughly 6 to 12 weeks, but the populations, formulations, and outcomes differed. Some amounts were tested as purified pterostilbene, some as a standardized plant extract, and some only in multi-ingredient combinations. ^{3, 4, 6, 7, 8}

The 100 and 250 mg per day amounts from the cholesterol trial are research exposures, not consumer targets. The LDL signal also makes a more-is-better interpretation especially inappropriate. No universally accepted maintenance dose, therapeutic dose, or validated long-term upper limit has been established.

In the 6 to 8 week cholesterol trial, reported adverse events and measured liver, kidney, and glucose laboratory values did not differ significantly from placebo. The safety analysis was small and short, did not include every relevant clinical test, and cannot exclude uncommon, delayed, or long-term effects. ³

The LDL increase remains relevant even when a participant feels no immediate side effect. A supplement should not be described as proven safe up to 250 mg per day on the basis of a short study.

Anyone taking prescription medicines should have the complete formula reviewed by a clinician or pharmacist who can see the medicine list and health context. The laboratory enzyme result is a reason for uncertainty and further clinical study, not a complete list of proven interactions.